E2F1/7/8在宫颈癌中的研究进展

Research progress of E2F1/7/8 in cervical cancer

摘要

转录因子1 （E2F1）是转录因子E2F家族研究最多的成员，主要参与细胞周期、细胞增殖与分化的调节，E2F1的高表达与肿瘤的发生发展及患者预后密切相关，发挥促癌作用。转录因子7 （E2F7）和转录因子8 （E2F8）是近期发现的非典型 E2F 转录因子家族成员，E2F7/8 的异常表达与肿瘤患者的预后具有一定相关性，发挥抑瘤作用。随着E2F1/7/8 在肿瘤（肝癌和肺癌）中的研究不断深入，E2F1/7/8与宫颈癌的发生发展有望为宫颈癌的诊断和治疗提供新的理论参考。本文通过综述E2F1/7/8在宫颈癌中的相关机制，以期为未来宫颈癌的相关研究奠定基础。

Abstract

Transcription factor 1 (E2F1) is the most extensively studied member of the transcription factor E2F family. It is mainly involved in the regulation of the cell cycle, cell proliferation, and differentiation. Moreover, the high expression of E2F1 is closely related to the occurrence and development of tumors, and the prognosis of patients, playing a role in promoting cancer. Transcription factor 7 (E2F7) and transcription factor 8 (E2F8) are the recently discovered members of the atypical E2F transcription factor family. The abnormal expression of E2F7/8 has a certain correlation with the prognosis of tumor patients, exerting an anti-tumor effect. With the deepening of research on E2F1, E2F7, and E2F8 in tumors (such as liver cancer and lung cancer), their relationship with the occurrence and development of cervical cancer is expected to provide a new theoretical reference for its diagnosis and treatment. Therefore, this article reviews the related mechanisms of E2F1, E2F7, and E2F8 in cervical cancer, in the hope of laying a foundation for future related studies.

关键词

宫颈癌 / 转录因子1 / 转录因子7 / 转录因子8

Key words

Cervical cancer / Transcription factor 1 / Transcription factor 7 / Transcription factor 8

参考文献

[1] 张希 , 杨雷 , 刘硕 , 等. 2022 年全球恶性肿瘤统计报告解读[J]. 中华肿瘤杂志, 2024, 46(7): 710-721.

[2] OLUSOLA P, BANERJEE H N, PHILLEY J V, et al. Human papilloma virus-associated cervical cancer and health disparities[J]. Cells, 2019, 8(6): 622.

[3] American Cancer Society. Key Statistics for Cervical Cancer[EB/OL]: (2021) [2025-08-19]. https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html.

[4] FENG C H, MELL L K, SHARABI A B, et al. Immunotherapy with radiotherapy and chemoradiotherapy for cervical cancer[J]. Seminars in Radiation Oncology, 2020, 30 (4): 273-280.

[5] KENT L N, LEONE G. The broken cycle: E2F dysfunction in cancer[J]. Nature Review Cancer, 2019, 19(6): 326-338.

[6] CHEN R, ZHANG Z, HU B, et al. Identification of the expression and clinical significance of E2F family in clear cell renal cell carcinoma[J]. International Journal of General Medicine, 2022: 1193-1212.

[7] SUN C C, ZHOU Q, HU W, et al. Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma[J]. Aging (Albany NY), 2018, 10(5): 973-987.

[8] YANG C, ZHANG Z C, LIU T B, et al. E2F1/2/7/8 as independent indicators of survival in patients with cervical squamous cell carcinoma[J]. Cancer Cell International, 2020, 20: 500.

[9] FANG Z, LIN M, LI C, et al. A comprehensive review of the roles of E2F1 in colon cancer[J]. American Journal of Cancer Research, 2020, 10(3): 757-768.

[10] LIN S, YU X, YAN H, et al. E2F7 serves as a potential prognostic biomarker for lung adenocarcinoma[J]. Medicine, 2024, 103(3): e34342.

[11] YU H, LI Z, WANG M. Expression and prognostic role of E2F transcription factors in high-grade glioma[J]. CNS Neuroscience & Therapeutics, 2020, 26(7): 741-753.

[12] KIM L K, PARK S A, EOH K J, et al. E2F8 regulates the proliferation and invasion through epithelial-mesenchymal transition in cervical cancer[J]. International Journal of Biological Science, 2020, 16(2): 320-329.

[13] NAKAJIMA R, DEGUCHI R, KOMORI H, et al. The TFDP 1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F[J]. Biochemical and Biophysical Research Communications, 2023, 663154-663162.

[14] XU J, LIU L, MA R, et al. E2F 1 Induces KIF26A transcription and promotes cell cycle progression via CDK-RB-E2Fs feedback loop in breast cancer[J]. Frontiers in Oncology, 2021, 10: 530933.

[15] HAN W T, LIU M Y, HAN D, et al. Exploiting the tumor-suppressive activity of the androgen receptor by CDK4/6 inhibition in castration-resistant prostate cancer[J]. Molecular Therapy: The Journal of the American Society of Gene Therapy, 2022, 30(4): 1628-1644.

[16] GOEL S, BERGHOLZ J S, ZHAO J J. Targeting CDK4 and CDK6 in cancer[J]. Nature Reviews Cancer, 2022, 22 (6): 356-372.

[17] DU Q, GUO X, WANG M, et al. The application and prospect of CDK4/6 inhibitors in malignant solid tumors[J]. Journal of Hematology & Oncology, 2020, 13(1): 41.

[18] WU Y, YOU Z, XU M. Genetic polymorphism of E2F1 influences susceptibility to ovarian cancer in a Chinese Population[J]. Contrast Media & Molecular Imaging, 2022, 2022 (1): 7808726.

[19] MORENO E, TOUSSAINT M J M, VAN ESSEN S C, et al. E2F7 is a potent inhibitor of liver tumor growth in adult mice[J]. Hepatology, 2021, 73(1): 303-317.

[20] CHUN J N, CHO M, SO I, et al. Emerging role of E2F8 in human cancer[J]. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2023, 1869(6): 166745.

[21] 孔德慧, 吴力钊. E2F8 在恶性肿瘤中的作用及机制研究进展[J]. 现代肿瘤医学, 2022, 30(11): 2094-2097.

[22] HAWKINS C C, JONES A B, GORDON E R, et al. Carmofur prevents cell cycle progression by reducing E2F8 transcription in temozolomide-resistant glioblastoma cells[J]. Cell Death Discovery, 2023, 9(1): 451.

[23] SERRANO B, BROTONS M, BOSCH F X, et al. Epidemiology and burden of HPV-related disease[J]. Best Practice & Research Clinical Obstetrics & Gynaecology, 2018, 47: 14-26.

[24] PAL A, KUNDU R. Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy[J]. Front Microbiol, 2019, 10: 3116.

[25] JOHNSON M E, CANTALUPO P G, PIPAS J M. Identification of head and neck cancer subtypes based on human papillomavirus presence and E2F-regulated gene expression [J]. mSphere, 2018, 3(1): E00580-17.

[26] 廖旭慧, 周璐青, 卢洪胜, 等 . HPV 感染宫颈病变组织中 E2F1 和 P-Akt 及 miR-424 与 COX-2 mRNA 水平[J]. 中华医院感染学杂志, 2023, 33(19): 2984-2988.

[27] SUN H, MA H, ZHANG H, et al. Up-regulation of MELK by E2F 1 promotes the proliferation in cervical cancer cells [J]. International Journal of Biological Sciences, 2021, 17 (14): 3875-3888.

[28] ZONG S, LIU X, ZHOU N, et al. E2F7, EREG, miR- 451a and miR-106b-5p are associated with the cervical cancer development[J]. Archives of Gynecology and Obstetrics, 2019, 299(4): 1089-1098.

[29] 周晖, 刘昀昀, 罗铭, 等. 《2024 NCCN 子宫颈癌临床实践指南（第 1 版）》更新解读［J］. 中国实用妇科与产科杂志, 2023, 39(11): 1119-1121.

[30] MARIMA R, MOSOANE B, MTSHALI N, et al. Mechanisms of chemotherapy resistance in cervical cancer[M]// Strategies for Overcoming Chemotherapy Resistance in Cervical Cancer. Amsterdam: Elsevier, 2024: 53-70.

[31] 徐欣, 张珊, 廖丽鑫, 等. 基于生物信息学方法和免疫组化分析 FASN 在宫颈癌组织的表达及临床意义[J]. 生物医学转化, 2024, 5(1): 101-107, 116.

基金资助

甘肃省自然科学基金项目(22JR5RA683)

甘肃省人民医院青年培育项目(23GSSYE-8)